BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Notice of Pendency and Proposed Settlement of Stockholder
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE BRAINSTORM CELL Lead Case No. 1:24-cv-01095-DEH THERAPEUTICS, INC. DERIVATIVE LITIGATION EXHIBIT C NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS TO: ALL RECORD HOLDERS AND
How this was made
The 30-second read
Why it matters
If the court approves, current stockholders are barred from contesting the settlement and pursuing released claims, and the company will benefit from specified corporate governance reforms. However, the notice summarizes allegations involving FDA invalidation of a hypothesis, manufacturing deficiencies, and safety concerns in the NurOwn Phase 3 trial.
Market read
This is a litigation-resolution catalyst that can reduce overhang, but it also keeps prominent the FDA and disclosure-related allegations that may continue to influence valuation.
What to watch
Court approval timing, potential fee/service award scrutiny, and whether the governance reforms are substantive enough to change future FDA interaction and reporting practices.
Background
The 8-K Item 7.01 furnishes a notice of pendency and proposed settlement for Brainstorm Cell Therapeutics stockholder derivative matters, alongside a related Delaware Section 220 books-and-records action.
Ticker impact
Brainstorm Cell Therapeutics filed an 8-K describing a proposed settlement and dismissal with prejudice of its stockholder derivative litigation, including FDA-related allegations.
Likely modest relief bid on settlement approval odds, with continued headline risk if investors focus on the alleged FDA and disclosure issues.
The filing is a court notice of pendency and proposed settlement, not a merits ruling. It signals progress toward resolution and governance reforms, but it also reiterates serious alleged misconduct tied to FDA communications and trial safety concerns.
Market effects
For biotech, derivative settlements tied to FDA communications can reinforce investor focus on disclosure quality and trial safety narratives.
Limited, primarily affecting US small-cap biotech sentiment and litigation-risk pricing.
Low, as this is company-specific litigation in US courts.
Counterpoint
Even with a settlement, investors may treat the reiterated FDA and misstatement allegations as a negative signal about historical regulatory and clinical risk, limiting any relief rally.
Key entities
- issuerBrainstorm Cell Therapeutics Inc.
Nominal defendant in the derivative action and subject of the proposed settlement notice.
- courtUnited States District Court for the Southern District of New York
Will hold a hearing to consider fairness, reasonableness, and adequacy of the proposed settlement.
- courtDelaware Court of Chancery
Has a pending Section 220 inspection action related to books and records.


